Rheumatoid Arthritis Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

According to the latest market report by the publisher, the global revenue from the rheumatoid arthritis market is projected to grow at a compound annual growth rate (CAGR) of 5.4%, reaching a valuation of about USD$1.10 billion by the end of 2031 from US$764.2 million in 2024. The market is expected to see substantial growth over the forecast period, contributing significantly to the global autoimmune disease diagnostics market.

Rising Demand for Advanced Diagnostic Solutions

Rheumatoid arthritis (RA) is an autoimmune disease characterized by swelling, warmth, and pain due to inflammation of the connective tissue, joints, muscles, tendons, and fibrous tissue. The disease primarily affects the hands, wrists, and feet and is more prevalent in women than men. Early diagnosis and treatment are crucial as RA is incurable. The development of rapid diagnostic test solutions with high specificity and sensitivity is essential to reduce the time and effort required for sample testing.

The global market for rheumatoid arthritis diagnostics and treatments is expected to witness significant growth due to the increasing prevalence of the disease and the rising demand for advanced diagnostic solutions. According to the World Health Organization (WHO), rheumatoid arthritis affects up to 14 million people globally. A study published in Frontiers in Medicine in 2022 highlighted that RA is prevalent among 5% of the population suffering from chronic inflammatory arthritis.

Government Initiatives and Funding Boost Market Growth

Government initiatives and funding play a crucial role in the growth of the rheumatoid arthritis market. Increasing spending by government bodies to develop novel and cost-effective drugs for RA surveillance and treatment are among the key factors driving market growth. Governments are investing in research and development activities to reduce the burden of RA surveillance and treatment.

In 2020, the Centers for Disease Control and Prevention (CDC) provided data on statistics of arthritic patients and arthritis affecting factors on quality of life. The CDC's Arthritis Program, Chronic Disease Self-Management Program, and Physical Activity Programs are raising awareness and diagnosis of RA. These initiatives are expected to promote the growth of RA diagnosis over the forecast period.

Market Projections: USD 764.2 Million in 2024 andUSD 1.10 billion by 2031

The rheumatoid arthritis market is projected to reach USD 764.2 million by 2024 andUSD 1.10 billion by 2031, growing at a CAGR of 5.4%. The commercialization of rapid diagnostic test kits with high specificity and sensitivity is expected to increase the demand for RA diagnostic test kits and treatment efficacy monitoring test kits.

Challenges: Limited Specificity and Sensitivity of Test Kits

Despite the positive growth outlook, the market faces challenges related to the limited specificity and sensitivity of rheumatoid arthritis test kits. Conventional test methods, such as erythrocyte sedimentation rate (ESR) and rheumatoid factor (RF) tests, have limited specificity and sensitivity, leading to false positive outcomes. Innovative diagnostic test kits, such as antinuclear antibody (ANA) tests and anti-cyclic citrullinated peptide (anti-CCP) tests, offer higher specificity and sensitivity. However, the high costs of these tests pose a significant challenge to their widespread adoption.

Regional Insights: United States and Germany

The United States held around 14.5% of the global market share in 2022, driven by increasing awareness and government funding. According to the CDC, 58.5 million adults (24%) in the United States have arthritis, with significant costs for medical care and lost wages. The CDC's funding and programs support arthritis self-management education and physical activity, raising awareness about RA detection and treatment.

In Germany, the market held around 6.3% of the global share in 2022, with a focus on the diagnosis and management of juvenile idiopathic arthritis (JIA). The Pediatric Rheumatology Society in Germany (GKJR) and its PRO-KIND Initiative establish harmonized diagnostic and therapeutic strategies for JIA, promoting early prognosis, diagnosis, and appropriate treatment.

Segment Insights: Serology Tests and Diagnostic Laboratories

Serology tests, which held 67.5% of the global market share in 2022, are crucial for the early diagnosis and differentiation of rheumatoid arthritis. These tests detect antibodies produced after exposure to foreign substances or microorganisms, aiding in the diagnosis of autoimmune and immunodeficiency disorders.

Diagnostic laboratories, which held around 41.6% of the global market share in 2022, are preferred for conducting diagnostic tests critical for detecting the disease's initial stages and management. Early detection and treatment with disease-modifying anti-rheumatic drugs (DMARDs) are essential for disease control and prevention of joint injury and disability.

Competitive Analysis

• Abbott Diagnostics
• Antibodies Incorporated
• Beckman Coulter, Inc.
• Euro Diagnostica AB
• Thermo Fisher Scientific Inc.
• Qiagen N.V.
• F. Hoffmann-La Roche Ltd.
• Siemens Healthcare GmbH
• Janel Group (Antibodies Inc.)

Key Market Segmentation

Test Type

• Serology Tests
• Erythrocyte Sedimentation rheumatoid arthritis (ESR)
• Rheumatoid Factor (RF)
• Anti-cyclic Citrullinated Peptide (anti-CCP)
• Antinuclear Antibody (ANA)
• Uric Acid
• Other Test
• Monitoring rheumatoid arthritis Treatment Efficiency Tests
• Salicylate Level Count
• Muscle Enzyme Test
• Creatinine Test

End User

• Hospitals
• Diagnostic Laboratories
• Private Laboratories
• Public Laboratories
• Ambulatory Surgical Centers

Region

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa (MEA)

This product will be delivered within 1-3 business days.